Editas Medicine clears first hurdle for EDIT-401 hyperlipidaemia trial
Editas Medicine has received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration, clearing its Phase 1/2 Strive trial of EDIT-401 to begin dosing in patients with Heterozygous Familial Hypercholesterolaemia (HeFH). The Cambridge, Massachusetts-based company also confirmed it has submitted the trial for regulatory review in New Zealand, where approval would extend enrolment to patients in both countries.
The company said it remains on track to begin patient dosing before the end of 2026, with initial safety and tolerability data expected in the first quarter of 2027. Topline safety and efficacy data from Part 1, the dose-finding portion of the study, are anticipated later in 2027.
The science behind EDIT-401
EDIT-401 takes a mechanistically distinct approach to LDL-cholesterol lowering. Rather than silencing a gene, as rival RNA-interference approaches do, Editas uses what it describes as a gene upregulation strategy: directly editing the LDLR gene to increase expression of the LDL receptor protein, which clears LDL-C from the bloodstream. In preclinical studies in non-human primates, the candidate achieved a mean reduction of approximately 90 per cent or greater across multiple atherogenic lipoproteins, including LDL-C, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB).
New preclinical data to be presented at the American Heart Association Scientific Sessions on 8 November in Chicago will show that this roughly 90 per cent LDL-C reduction was sustained over ten months in an ongoing non-human primate study, supporting the potential durability of a single-dose treatment. Chief Medical Officer Dan Ory said the company was encouraged by these results and that they "further support its potential to provide durable, lifelong benefits to patients."
The Strive trial is designed in two parts. Part 1 is a single ascending dose, open-label, dose-finding study. Part 2 will expand to a single-dose randomised, placebo-controlled design. Editas has selected five sites across Australia and New Zealand.
Market context and competitive landscape
The LDL-lowering space is heavily contested. Statins remain the standard of care for the broad hyperlipidaemia population, while PCSK9 inhibitors, both monoclonal antibody-based (evolocumab, alirocumab) and small-molecule (inclisiran), have carved out a growing market in patients who require additional lowering. The RNA-interference agent inclisiran, which requires only twice-yearly dosing, has reset expectations around dosing convenience in this indication. A single-dose gene editing approach, if it delivers durable efficacy in the clinic, could represent a further step change, but the bar set by existing therapies is high.
Lp(a) lowering is a particularly active frontier. Several dedicated Lp(a)-targeting programmes are in late-stage development from larger rivals, and any agent that reduces Lp(a) substantially as part of a broader lipid-lowering profile may attract interest both clinically and commercially. Editas' claim that EDIT-401 reduces Lp(a) by around 90 per cent in preclinical models will attract scrutiny when human data emerge.
HeFH represents a well-characterised and underserved patient population. With an estimated 1.2 million people affected in the United States and many remaining undiagnosed, there is a clear clinical rationale for the programme. However, EDIT-401 remains at the earliest stage of human testing, and investors will rightly apply caution until Phase 1 safety data confirm the tolerability profile seen in preclinical work. The November AHA presentation will be closely watched as the last major preclinical data read-out before first-in-human results are expected.